Table of Contents
Overview
New York, NY – June 06, 2025 – Global Cholera Vaccines Market was valued at USD 94.5 million in 2024 and is anticipated to register substantial growth of USD 230.0 million by 2034, with 9.3% CAGR
Cholera vaccines have emerged as a vital public health intervention in the fight against the acute diarrheal disease caused by Vibrio cholerae. These vaccines are designed to stimulate immunity against cholera and are particularly important in endemic regions and during outbreaks caused by contaminated water and inadequate sanitation.
Currently, two main types of oral cholera vaccines (OCVs) are in use killed whole-cell vaccines and live attenuated vaccines. The most widely used OCVs include Dukoral, Shanchol, and Euvichol-Plus, all prequalified by the World Health Organization (WHO). These vaccines are safe, easy to administer, and provide protection ranging from 3 to 5 years with a two-dose regimen.
Cholera vaccination is recognized by WHO and UNICEF as a critical part of integrated cholera control strategies, particularly in emergency settings and high-risk populations. As of 2023, more than 135 million doses of OCVs have been distributed globally through the WHO-led global cholera vaccine stockpile.
Efforts to expand vaccine production and improve access are accelerating in response to rising cholera outbreaks, particularly in Africa, South Asia, and the Middle East. Strategic use of cholera vaccines, combined with investments in water, sanitation, and hygiene (WASH), is essential to achieving the global goal of reducing cholera deaths by 90% by 2030.
Key Takeaways
- The global cholera vaccines market was valued at USD 94.5 million in 2024 and is projected to reach USD 230.0 million by 2034, expanding at a compound annual growth rate (CAGR) of 9.3% over the forecast period.
- In 2024, the Dukoral segment dominated the global market, accounting for 33.4% of the total revenue share, reflecting strong preference for oral inactivated vaccines.
- The hospital pharmacy segment emerged as the leading distribution channel in 2024, capturing 46.2% of the market share, driven by increased institutional vaccination programs.
- North America led the global cholera vaccines market in 2024, contributing 38.4% of the total revenue, supported by advanced healthcare infrastructure and rising public health awareness.
Segmentation Analysis
Product Type Analysis: In 2024, the Dukoral segment led the global cholera vaccines market, accounting for 33.4% of the total share. Dukoral, an oral inactivated vaccine developed by Valneva and licensed to Emergent BioSolutions, is widely used for both endemic protection and travel immunization. Its dual efficacy against cholera and ETEC-related diarrhea enhances its global demand. Endorsements by the WHO and other regulatory bodies, along with convenient oral administration, further drive its adoption across both public health and private sectors.
Distribution Channel Analysis: In 2024, the hospital pharmacy segment dominated the cholera vaccines market with a 46.2% revenue share. Hospitals play a crucial role in vaccine deployment during outbreaks and travel immunization campaigns. Their ability to ensure rapid administration, proper storage, and cold chain compliance makes them central to vaccination efforts. Additionally, public immunization programs and government-led initiatives often rely on hospital pharmacies for safe and efficient vaccine distribution, reinforcing their importance within the healthcare delivery system.
Market Segments
Product Type
- Dukoral
- Vaxchora
- Shanchol
- Other
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Other
Regional Analysis
North America held a leading position in the cholera vaccines market in 2024, driven by its advanced healthcare infrastructure and strong immunization policies. High public awareness, combined with support from agencies such as the Centers for Disease Control and Prevention (CDC) and the World Health Organization (WHO), has significantly boosted the demand for cholera vaccines, particularly for travelers heading to endemic regions.
The region’s dominance is further supported by the presence of major pharmaceutical manufacturers, ongoing investments in vaccine research, and widespread access through hospital pharmacies, travel clinics, and retail outlets. A high uptake of travel-related vaccinations, especially among individuals and defense personnel, reinforces North America’s substantial market share.
Emerging Trends
- Escalating Global Cholera Incidence: Cholera cases have been on the rise globally. In 2023, there was a 13% increase in reported cases and a 71% increase in deaths compared to 2022. Over 4,000 fatalities were recorded in 2023 alone. Notably, 38% of these cases were among children under five years of age. This surge is attributed to factors such as inadequate access to clean water, sanitation, and healthcare services, particularly in conflict-affected regions.
- Cholera Vaccine Shortages and Strategic Adjustments: The global stockpile of Oral Cholera Vaccines (OCVs) has faced significant shortages. As of October 2024, the stockpile was entirely depleted, hindering outbreak response efforts. To address this, the standard two-dose vaccination regimen was temporarily suspended in favor of a single-dose approach, allowing for broader coverage despite reduced individual immunity duration.
- Advancements in Vaccine Development: Efforts are underway to enhance vaccine production and efficacy. In 2024, the WHO prequalified Euvichol-S, a simplified oral cholera vaccine designed to reduce production costs and increase supply. Additionally, Bharat Biotech’s Hillchol vaccine demonstrated promising results in phase III trials in India, with over 68% of participants showing a fourfold increase in antibody levels. The company has the capacity to produce up to 200 million doses annually, potentially alleviating global shortages.
- Targeted Vaccination Campaigns in High-Risk Areas: Mass vaccination campaigns have been implemented in vulnerable regions. For instance, in January 2025, a campaign in Cox’s Bazar, Bangladesh, administered over 1.4 million doses to Rohingya refugees. A subsequent campaign in April 2025 targeted approximately 166,661 children aged 1 to 5 years, who accounted for 39% of cholera cases in the area.
- Integration of Rapid Diagnostic Tools: The deployment of rapid diagnostic tests (RDTs) is enhancing cholera surveillance and response. These tests provide results within 15 minutes, facilitating timely outbreak detection and management. The initiative, coordinated by Gavi and WHO, aims to strengthen routine surveillance and inform preventive programs.
Use Cases
- Emergency Outbreak Response: OCVs are critical in controlling cholera outbreaks. Between January and February 2025, 70,488 cases and 808 deaths were reported across 23 countries. The availability of vaccines during such emergencies is vital to curb the spread and reduce mortality.
- Preventive Measures in Endemic Regions: In areas where cholera is endemic, preventive vaccination campaigns are essential. Since the establishment of the global OCV stockpile in 2013, over 50 million doses have been administered in various settings to prevent outbreaks.
- Protection of Displaced Populations: Refugee camps and areas with displaced populations are particularly susceptible to cholera due to overcrowding and limited sanitation. Targeted vaccination efforts, such as those in Cox’s Bazar, are crucial in these settings to prevent disease spread among vulnerable groups.
- Supplementing Water, Sanitation, and Hygiene (WASH) Initiatives: While improving water and sanitation infrastructure is the long-term solution to cholera, vaccines serve as an immediate protective measure. They act as a bridge, providing protection until sustainable WASH solutions are implemented.
- Global Health Security and Preparedness: Cholera vaccines are integral to global health security strategies. They are included in emergency preparedness plans to ensure rapid response capabilities in the event of outbreaks, thereby minimizing the impact on affected populations.
Conclusion
Cholera vaccines play a crucial role in global health by providing rapid and effective protection against a disease driven by poor sanitation and water access. With rising outbreaks, especially in high-risk regions, strategic use of vaccines like Dukoral, Shanchol, and Euvichol-Plus, along with targeted immunization efforts, is essential.
Vaccine shortages and increasing global incidence underscore the need for expanded production and equitable distribution. When integrated with water, sanitation, and hygiene (WASH) programs, cholera vaccination significantly contributes to WHO’s 2030 goal of reducing cholera deaths by 90%, reinforcing its value in global health security and preparedness.
Discuss your needs with our analyst
Please share your requirements with more details so our analyst can check if they can solve your problem(s)
